Merck announced that Juvisync, a fixed-dose combination product containing the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin and the HMG-CoA reductase inhibitor simvastatin is now available. Sitagliptin is approved for use in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. Simvastatin is indicated for use with diet and exercise to treat multiple hyperlipoproteinemias. This combination product is indicated for patients who require treatment with both of these drugs.

Juvisync is available in 100mg/10mg, 100mg/20mg, and 100mg/40mg dosage strengths.
For more information call (800) 444-2080 or visit